Overcoming Acquired Resistance With Second-Generation TRK Inhibitors

In this podcast episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss emerging data on the efficacy, safety, and clinical role of second-generation TRK inhibitors that can overcome acquired resistance to first-generation agents in NTRK fusion–positive solid tumors. Topics include:Mechanisms of acquired resistance to TRK inhibitor therapyClinical trial data on the second-generation inhibitors selitrectinib and repotrectinibSafety profiles of first- vs second-generation TRK inhibitorsPresenters:George D. Demetri, MDProfessor of MedicineHarvard Medical SchoolHarvard UniversityCo-Director, Ludwig Center at HarvardSenior Vice President for Experimental TherapeuticsDirector, Sarcoma CenterDana-Farber Cancer InstituteBoston, MassachusettsAlexander Drilon, MDChief, Early Drug DevelopmentAttending, ThoracicMemorial Sloan Kettering Cancer CenterNew York, New YorkLink to full program, including downloadable slides:https://bit.ly/2YFIPfr Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.